MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-12-2025
AcelRx Pharmaceuticals DSO Ratio 2011-2026 | ACRX
Annual DSO Ratio AcelRx Pharmaceuticals
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | 16.5 | 51.5 | 42.8 | 82.9 | 68 | 70 | 123 | 62.3 | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 123 | 16.5 | 64.6 |
Quarterly DSO Ratio AcelRx Pharmaceuticals
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | - | - | 78.8 | 43.9 | 35.5 | - | 6.3 | 78.5 | 115 | - | 42.4 | 19.8 | 126 | 83 | 64.8 | 41.9 | 82.8 | 7.29 | 11.9 | 5.47 | 210 | 189 | 94.1 | 52.6 | 108 | 82.7 | 158 | 117 | 138 | 173 | 19.4 | 156 | 828 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 828 | 5.47 | 109 |
DSO Ratio of other stocks in the Drug manufacturers industry
| Issuer | DSO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Aerie Pharmaceuticals
AERI
|
117 | - | - | $ 754 M |  USA |
 |
Catalent
CTLT
|
80.1 | - | - | $ 11.5 B | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
71.7 | - | 0.86 % | $ 117 M | USA |
 |
DURECT Corporation
DRRX
|
100 | - | - | $ 50.1 M | USA |
 |
Canopy Growth Corporation
CGC
|
62.7 | $ 1.06 | -0.93 % | $ 114 M |  Canada |
 |
Endo International plc
ENDP
|
79.9 | - | - | $ 28.9 M |  Irlanda |
 |
Agile Therapeutics
AGRX
|
63.1 | - | 10.11 % | $ 58.2 M | USA |
 |
Evoke Pharma
EVOK
|
45.7 | - | - | $ 36.6 M | USA |
 |
Alimera Sciences
ALIM
|
122 | - | - | $ 142 M | USA |
 |
Cronos Group
CRON
|
203 | $ 2.6 | -1.14 % | $ 1.35 B | Canada |
 |
Avadel Pharmaceuticals plc
AVDL
|
49.9 | - | - | $ 2.06 B |  France |
 |
Jupiter Wellness
JUPW
|
134 | - | - | $ 33.6 M | USA |
 |
China Pharma Holdings
CPHI
|
29.7 | $ 0.55 | -3.51 % | $ 9.61 M |  China |
 |
Cumberland Pharmaceuticals
CPIX
|
375 | $ 4.58 | -5.37 % | $ 64.4 M | USA |
 |
HEXO Corp.
HEXO
|
71.3 | - | 2.45 % | $ 38.1 M | Canada |
 |
Neoleukin Therapeutics
NLTX
|
3.46 | - | - | $ 193 M | Canada |
 |
Aurora Cannabis
ACB
|
99.8 | $ 3.48 | -6.2 % | $ 86.3 M | Canada |
 |
Athenex
ATNX
|
89.9 | - | -23.39 % | $ 1.76 M | USA |
 |
Harrow Health
HROW
|
152 | $ 38.6 | -27.96 % | $ 1.42 B | USA |
 |
Emergent BioSolutions
EBS
|
60.9 | $ 8.92 | -0.78 % | $ 457 M | USA |
 |
ProPhase Labs
PRPH
|
111 | - | - | $ 5.07 M | USA |
 |
Assertio Holdings
ASRT
|
112 | $ 11.9 | 1.06 % | $ 845 M | USA |
 |
Radius Health
RDUS
|
16.1 | - | - | $ 1.42 B | USA |
 |
Evolus
EOLS
|
62.9 | $ 4.13 | -3.73 % | $ 266 M | USA |
 |
Bausch Health Companies
BHC
|
78.9 | $ 5.73 | -3.7 % | $ 2.09 B | Canada |
 |
Lannett Company
LCI
|
83.1 | - | 1.15 % | $ 7.11 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
65.5 | - | -39.89 % | $ 27.7 M | USA |
 |
Organogenesis Holdings
ORGO
|
72.6 | $ 2.87 | -4.33 % | $ 378 M | USA |
 |
OrganiGram Holdings
OGI
|
93 | $ 1.37 | -3.52 % | $ 402 M | Canada |
 |
Perrigo Company plc
PRGO
|
53.9 | $ 11.39 | -7.89 % | $ 1.58 B | USA |
 |
Rockwell Medical
RMTI
|
37.5 | $ 0.9 | -0.12 % | $ 21 M | USA |
 |
TherapeuticsMD
TXMD
|
2.3 K | $ 2.22 | -0.89 % | $ 23.2 M | USA |
 |
Veru
VERU
|
91.5 | $ 2.52 | -3.82 % | $ 340 M | USA |
 |
Viatris
VTRS
|
78.8 | $ 14.89 | -5.16 % | $ 17.9 B | USA |
 |
cbdMD
YCBD
|
11.3 | $ 0.77 | -4.37 % | $ 3.32 M | USA |
 |
Pacira BioSciences
PCRX
|
50.3 | $ 22.1 | 3.85 % | $ 1.02 B | USA |
 |
PetIQ
PETQ
|
43.1 | - | 1.64 % | $ 400 M | USA |
 |
OptiNose
OPTN
|
138 | - | - | $ 1.08 B | USA |
 |
PLx Pharma
PLXP
|
14.1 | - | -27.8 % | $ 2.56 M | USA |
 |
Recro Pharma
REPH
|
62.7 | - | -4.76 % | $ 65.3 M | USA |
 |
SCYNEXIS
SCYX
|
106 | $ 0.75 | 0.33 % | $ 35.9 M | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
65.5 | $ 2.75 | -3.17 % | $ 3.41 M | USA |
 |
Tilray
TLRY
|
52.8 | $ 7.36 | -3.16 % | $ 4.55 B | Canada |
 |
Zynerba Pharmaceuticals
ZYNE
|
14.6 K | - | - | $ 55.5 M | USA |